Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice.

Marino S, de Ridder D, Bishop RT, Renema N, Ponzetti M, Sophocleous A, Capulli M, Aljeffery A, Carrasco G, Gens MD, Khogeer A, Ralston SH, Gertsch J, Lamoureux F, Heymann D, Rucci N, Idris AI.

EBioMedicine. 2019 May 28. pii: S2352-3964(19)30356-1. doi: 10.1016/j.ebiom.2019.05.048. [Epub ahead of print]

2.

Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients.

Duflot T, Moreau-Grangé L, Roche C, Iacob M, Wils J, Rémy-Jouet I, Cailleux AF, Leuillier M, Renet S, Li D, Morisseau C, Lamoureux F, Richard V, Prévost G, Joannidès R, Bellien J.

Cardiovasc Diabetol. 2019 Mar 18;18(1):35. doi: 10.1186/s12933-019-0843-z.

3.

Analysis of mRNA, miRNA, and DNA in Bone Cells by RT-qPCR and In Situ Hybridization.

Moukengue B, Amiaud J, Jacques C, Charrier C, Ory B, Lamoureux F.

Methods Mol Biol. 2019;1914:169-196. doi: 10.1007/978-1-4939-8997-3_9.

PMID:
30729465
4.

Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma.

Georges S, Calleja LR, Jacques C, Lavaud M, Moukengue B, Lecanda F, Quillard T, Gabriel MT, Cartron PF, Baud'huin M, Lamoureux F, Heymann D, Ory B.

Oncotarget. 2018 Nov 6;9(87):35726-35741. doi: 10.18632/oncotarget.26284. eCollection 2018 Nov 6.

5.

The right blood collection tube for therapeutic drug monitoring and toxicology screening procedures: Standard tubes, gel or mechanical separator?

Schrapp A, Mory C, Duflot T, Pereira T, Imbert L, Lamoureux F.

Clin Chim Acta. 2019 Jan;488:196-201. doi: 10.1016/j.cca.2018.10.043. Epub 2018 Nov 12.

PMID:
30439354
6.

Isavuconazole Kinetic Exploration for Clinical Practice.

Darnaud L, Lamoureux F, Godet C, Pontier S, Debard A, Venisse N, Martins P, Concordet D, Gandia P.

Drugs R D. 2018 Dec;18(4):317-321. doi: 10.1007/s40268-018-0251-y.

7.

Implication of molecular vascular smooth muscle cell heterogeneity among arterial beds in arterial calcification.

Espitia O, Chatelais M, Steenman M, Charrier C, Maurel B, Georges S, Houlgatte R, Verrecchia F, Ory B, Lamoureux F, Heymann D, Gouëffic Y, Quillard T.

PLoS One. 2018 Jan 26;13(1):e0191976. doi: 10.1371/journal.pone.0191976. eCollection 2018.

8.

Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases.

Duflot T, Marie-Cardine A, Verstuyft C, Filhon B, Pereira T, Massy-Guillemant N, Joannidès R, Bellien J, Lamoureux F.

Fundam Clin Pharmacol. 2018 Jun;32(3):337-342. doi: 10.1111/fcp.12345. Epub 2018 Jan 25.

PMID:
29319893
9.

Impact of CYP3A4 Genotype on Voriconazole Exposure.

Duflot T, Schrapp A, Bellien J, Lamoureux F.

Clin Pharmacol Ther. 2018 Feb;103(2):185-186. doi: 10.1002/cpt.809. Epub 2017 Aug 29. No abstract available.

PMID:
28786228
10.

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).

Lamoureux F, Duflot T; French Network of Pharmacogenetics (RNPGX).

Therapie. 2017 Apr;72(2):257-267. doi: 10.1016/j.therap.2016.09.017. Epub 2017 Jan 30. Review.

PMID:
28237404
11.

Pharmacogénétique en cardiovasculaire : état des connaissances et des pratiques – recommandations du Réseau national de pharmacogénétique (RNPGx).

Lamoureux F, Duflot T; le Réseau national de pharmacogénétique.

Therapie. 2017 Apr;72(2):245-255. doi: 10.1016/j.therap.2016.09.010. Epub 2017 Jan 3. French. No abstract available.

PMID:
28126189
12.

Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis.

Tellez-Gabriel M, Ory B, Lamoureux F, Heymann MF, Heymann D.

Int J Mol Sci. 2016 Dec 20;17(12). pii: E2142. doi: 10.3390/ijms17122142. Review.

13.

A sensitive LC-MS/MS method for the quantification of regioisomers of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids in human plasma during endothelial stimulation.

Duflot T, Pereira T, Roche C, Iacob M, Cardinael P, Hamza NE, Thuillez C, Compagnon P, Joannidès R, Lamoureux F, Bellien J.

Anal Bioanal Chem. 2017 Mar;409(7):1845-1855. doi: 10.1007/s00216-016-0129-1. Epub 2016 Dec 15.

PMID:
27981341
14.

Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis.

Baud'huin M, Lamoureux F, Jacques C, Rodriguez Calleja L, Quillard T, Charrier C, Amiaud J, Berreur M, Brounais-LeRoyer B, Owen R, Reilly GC, Bradner JE, Heymann D, Ory B.

Bone. 2017 Jan;94:10-21. doi: 10.1016/j.bone.2016.09.020. Epub 2016 Sep 23.

15.

miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors.

Jacques C, Calleja LR, Baud'huin M, Quillard T, Heymann D, Lamoureux F, Ory B.

Oncotarget. 2016 Aug 23;7(34):54503-54514. doi: 10.18632/oncotarget.10950.

16.

Corrigendum re: "Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer" [Eur Urol 2014;66:145-55].

Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.

Eur Urol. 2016 Jul;70(1):e27-e28. doi: 10.1016/j.eururo.2016.03.014. Epub 2016 Mar 31. No abstract available.

PMID:
27302299
17.

Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.

Jacques C, Lamoureux F, Baud'huin M, Rodriguez Calleja L, Quillard T, Amiaud J, Tirode F, Rédini F, Bradner JE, Heymann D, Ory B.

Oncotarget. 2016 Apr 26;7(17):24125-40. doi: 10.18632/oncotarget.8214.

18.

ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis.

Rodriguez Calleja L, Jacques C, Lamoureux F, Baud'huin M, Tellez Gabriel M, Quillard T, Sahay D, Perrot P, Amiaud J, Charrier C, Brion R, Lecanda F, Verrecchia F, Heymann D, Ellisen LW, Ory B.

Cancer Res. 2016 Jun 1;76(11):3236-51. doi: 10.1158/0008-5472.CAN-15-2317. Epub 2016 Mar 17.

19.

Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.

Lamoureux F, Duflot T, Woillard JB, Metsu D, Pereira T, Compagnon P, Morisse-Pradier H, El Kholy M, Thiberville L, Stojanova J, Thuillez C.

Int J Antimicrob Agents. 2016 Feb;47(2):124-31. doi: 10.1016/j.ijantimicag.2015.12.003. Epub 2015 Dec 21.

PMID:
26775563
20.

Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.

Ory B, Baud'huin M, Verrecchia F, Royer BB, Quillard T, Amiaud J, Battaglia S, Heymann D, Redini F, Lamoureux F.

Clin Cancer Res. 2016 May 15;22(10):2520-33. doi: 10.1158/1078-0432.CCR-15-1925. Epub 2015 Dec 28.

21.

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.

Lamoureux F, Baud'huin M, Ory B, Guiho R, Zoubeidi A, Gleave M, Heymann D, Rédini F.

Oncotarget. 2014 Sep 15;5(17):7805-19.

22.

Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.

Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, Bishop JL, Zoubeidi A.

Oncogenesis. 2014 Aug 18;3:e115. doi: 10.1038/oncsis.2014.30.

23.

BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.

Gobin B, Huin MB, Lamoureux F, Ory B, Charrier C, Lanel R, Battaglia S, Redini F, Lezot F, Blanchard F, Heymann D.

Int J Cancer. 2015 Feb 15;136(4):784-96. doi: 10.1002/ijc.29040. Epub 2014 Jun 30.

24.

Invasive Geotrichum clavatum fungal infection in an acute myeloid leukaemia patient: a case report and review.

Camus V, Thibault ML, David M, Gargala G, Compagnon P, Lamoureux F, Girault C, Michot JB, Stamatoullas A, Lanic H, Jardin F, Lenain P, Tilly H, Leprêtre S.

Mycopathologia. 2014 Jun;177(5-6):319-24. doi: 10.1007/s11046-014-9746-4. Epub 2014 Apr 20.

PMID:
24748454
25.

Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle.

Lamoureux F, Baud'huin M, Rodriguez Calleja L, Jacques C, Berreur M, Rédini F, Lecanda F, Bradner JE, Heymann D, Ory B.

Nat Commun. 2014 Mar 19;5:3511. doi: 10.1038/ncomms4511.

26.

Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.

Odri G, Kim PP, Lamoureux F, Charrier C, Battaglia S, Amiaud J, Heymann D, Gouin F, Redini F.

BMC Cancer. 2014 Mar 10;14:169. doi: 10.1186/1471-2407-14-169.

27.

Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.

Duflot T, Roche C, Lamoureux F, Guerrot D, Bellien J.

Expert Opin Drug Discov. 2014 Mar;9(3):229-43. doi: 10.1517/17460441.2014.881354. Epub 2014 Feb 4. Review.

PMID:
24490654
28.

Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.

Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.

Eur Urol. 2014 Jul;66(1):145-55. doi: 10.1016/j.eururo.2013.12.019. Epub 2013 Dec 29. Erratum in: Eur Urol. 2016 Jul;70(1):e27-e28.

29.

Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL.

Picarda G, Matous E, Amiaud J, Charrier C, Lamoureux F, Heymann MF, Tirode F, Pitard B, Trichet V, Heymann D, Redini F.

J Bone Oncol. 2013 May 20;2(3):95-104. doi: 10.1016/j.jbo.2013.04.004. eCollection 2013 Sep.

30.

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.

Mol Cancer Ther. 2013 Nov;12(11):2342-55. doi: 10.1158/1535-7163.MCT-13-0032. Epub 2013 Aug 21.

31.

Osteoprotegerin: multiple partners for multiple functions.

Baud'huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, Redini F, Heymann MF, Heymann D.

Cytokine Growth Factor Rev. 2013 Oct;24(5):401-9. doi: 10.1016/j.cytogfr.2013.06.001. Epub 2013 Jul 1. Review.

32.

Dual inhibition of autophagy and the AKT pathway in prostate cancer.

Lamoureux F, Zoubeidi A.

Autophagy. 2013 Jul;9(7):1119-20. doi: 10.4161/auto.24921. Epub 2013 May 6.

33.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

34.

Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.

Lamoureux F, Thomas C, Crafter C, Kumano M, Zhang F, Davies BR, Gleave ME, Zoubeidi A.

Clin Cancer Res. 2013 Feb 15;19(4):833-44. doi: 10.1158/1078-0432.CCR-12-3114. Epub 2012 Dec 20.

35.

Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth.

Surdez D, Benetkiewicz M, Perrin V, Han ZY, Pierron G, Ballet S, Lamoureux F, Rédini F, Decouvelaere AV, Daudigeos-Dubus E, Geoerger B, de Pinieux G, Delattre O, Tirode F.

Cancer Res. 2012 Sep 1;72(17):4494-503. Epub 2012 Aug 28.

36.

Mapping cyclosporine-induced changes in protein secretion by renal cells using stable isotope labeling with amino acids in cell culture (SILAC).

Lamoureux F, Gastinel LN, Mestre E, Marquet P, Essig M.

J Proteomics. 2012 Jun 27;75(12):3674-87. doi: 10.1016/j.jprot.2012.04.024. Epub 2012 Apr 27.

PMID:
22564819
37.

Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.

Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.

Prostate. 2012 Jun 1;72(8):875-85. doi: 10.1002/pros.21490. Epub 2011 Oct 5.

PMID:
22072572
38.

Quantitative proteomic analysis of cyclosporine-induced toxicity in a human kidney cell line and comparison with tacrolimus.

Lamoureux F, Mestre E, Essig M, Sauvage FL, Marquet P, Gastinel LN.

J Proteomics. 2011 Dec 21;75(2):677-94. doi: 10.1016/j.jprot.2011.09.005. Epub 2011 Sep 18.

PMID:
21964257
39.

Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.

Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A, Gleave ME.

Cancer Res. 2011 Sep 1;71(17):5838-49. doi: 10.1158/0008-5472.CAN-11-0994. Epub 2011 Jul 7.

40.

Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models.

Rousseau J, Escriou V, Lamoureux F, Brion R, Chesneau J, Battaglia S, Amiaud J, Scherman D, Heymann D, Rédini F, Trichet V.

J Bone Miner Res. 2011 Oct;26(10):2452-62. doi: 10.1002/jbmr.455.

41.

Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus.

Lamoureux F, Picard N, Boussera B, Sauvage FL, Marquet P.

Fundam Clin Pharmacol. 2012 Aug;26(4):463-72. doi: 10.1111/j.1472-8206.2011.00957.x. Epub 2011 Jun 1.

PMID:
21631587
42.

Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters.

Picard N, Levoir L, Lamoureux F, Yee SW, Giacomini KM, Marquet P.

Xenobiotica. 2011 Sep;41(9):752-7. doi: 10.3109/00498254.2011.573882. Epub 2011 Apr 27.

PMID:
21524191
43.

A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.

Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A.

Clin Cancer Res. 2011 Apr 15;17(8):2301-13. doi: 10.1158/1078-0432.CCR-10-3077. Epub 2011 Feb 24. Erratum in: Clin Cancer Res. 2011 Jul 15;17(14):4916.

44.

Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.

Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thüroff JW, Gleave ME.

Mol Cancer Ther. 2011 Feb;10(2):347-59. doi: 10.1158/1535-7163.MCT-10-0850. Epub 2011 Jan 7.

45.

Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.

Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F.

Cancer Res. 2010 Oct 1;70(19):7610-9. doi: 10.1158/0008-5472.CAN-09-4272. Epub 2010 Sep 14.

46.

Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.

Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F.

Clin Cancer Res. 2010 Apr 15;16(8):2363-74. doi: 10.1158/1078-0432.CCR-09-1779. Epub 2010 Apr 6.

47.

Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.

Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F.

Biochim Biophys Acta. 2010 Jan;1805(1):17-24. doi: 10.1016/j.bbcan.2009.08.004. Epub 2009 Sep 3. Review.

PMID:
19733222
48.

Determination of ethyl-glucuronide in hair for heavy drinking detection using liquid chromatography-tandem mass spectrometry following solid-phase extraction.

Lamoureux F, Gaulier JM, Sauvage FL, Mercerolle M, Vallejo C, Lachâtre G.

Anal Bioanal Chem. 2009 Aug;394(7):1895-901. doi: 10.1007/s00216-009-2863-0. Epub 2009 Jun 12.

PMID:
19517099
49.

Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.

Lamoureux F, Picarda G, Garrigue-Antar L, Baud'huin M, Trichet V, Vidal A, Miot-Noirault E, Pitard B, Heymann D, Rédini F.

Cancer Res. 2009 Jan 15;69(2):526-36. doi: 10.1158/0008-5472.CAN-08-2648.

50.

Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats.

Chauvin C, Philippeau JM, Hémont C, Hubert FX, Wittrant Y, Lamoureux F, Trinité B, Heymann D, Rédini F, Josien R.

Cancer Res. 2008 Nov 15;68(22):9433-40. doi: 10.1158/0008-5472.CAN-08-0104.

Supplemental Content

Loading ...
Support Center